A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It

Issued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ: CNXU) completed the P.R.O.O.F phase of its CXU preclinical program, the evidence base behind a focused first move into a roughly $11 billion medical aesthetics injectable market, an opening the company argues today's...